Stock analysts at Cantor Fitzgerald began coverage on shares of Arsanis (NASDAQ:ASNS) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $26.00 price target on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 110.70% from the company’s previous close.
A number of other brokerages have also weighed in on ASNS. Cowen initiated coverage on shares of Arsanis in a research note on Monday, December 11th. They issued an “outperform” rating for the company. Piper Jaffray Companies began coverage on shares of Arsanis in a research note on Monday, December 11th. They issued an “overweight” rating and a $23.00 target price for the company. ValuEngine upgraded shares of Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Citigroup began coverage on shares of Arsanis in a research note on Monday, December 11th. They set a “buy” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $25.33.
Arsanis (ASNS) traded down $0.44 on Wednesday, hitting $12.34. 2,500 shares of the company were exchanged, compared to its average volume of 15,335. Arsanis has a 1-year low of $10.40 and a 1-year high of $19.73.
Large investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in Arsanis in the 4th quarter valued at about $299,000. Landscape Capital Management L.L.C. acquired a new stake in Arsanis in the 4th quarter valued at about $504,000. Sphera Funds Management LTD. acquired a new stake in Arsanis in the 4th quarter valued at about $3,436,000. Finally, Monashee Investment Management LLC acquired a new stake in Arsanis in the 4th quarter valued at about $191,000.
WARNING: “Arsanis (ASNS) Research Coverage Started at Cantor Fitzgerald” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/arsanis-asns-research-coverage-started-at-cantor-fitzgerald.html.
Arsanis Company Profile
Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.